Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

NZE/GXH stock hub

NZE/GXH has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NZE/GXHis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

209.8M

New Zealand Stock Exchange

Market data

Price

Recent price action with selectable time range.

NZE/GXHNZE/GXH

—

Loading chart…

In the news

Latest news · NZE/GXH

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E12

P25 n/aP50 n/aP75 n/a

ROE12.5

P25 n/aP50 n/aP75 n/a

ROIC9.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NZE/GXH market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

240

Groups with data

Currency

NZD

Showing 240 of 240 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	New Zealand
Country code	NZ
Employees	5,700
Employees Change	0%
Employees Change Percent	0
Enterprise value	NZD 335.3M
Exchange	New Zealand Stock Exchange
Financial currency	NZD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	NZBDOE0001S8
Last refreshed	2026-05-10
Market cap	NZD 209.8M
Price	NZD 1.46
Price currency	NZD
Rev Per Employee	92,687.02x
Sector	Healthcare
Sic	5912
Symbol	nze/GXH
Website	https://www.greencrosshealth.co.nz

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	8.35%
EV Earnings	19.15x
EV/EBIT	8.35x
EV/EBITDA	5.6x
EV/FCF	8.52x
EV/Sales	0.63x
FCF yield	18.76%
P/B ratio	1.17x
P/E ratio	12.01x
P/S ratio	0.4x
PE Ratio10 Y	8.32x
PE Ratio3 Y	8.58x
PE Ratio5 Y	7.22x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	7.26%
EBITDA Margin	8.2%
FCF margin	7.45%
Gross margin	11.55%
Gross Profit	NZD 61M
Gross Profit Growth	2.31%
Gross Profit Growth Q	5.18%
Gross Profit Growth3 Y	3.55%
Gross Profit Growth5 Y	-2.65%
Net Income	NZD 17.5M
Net Income Growth	48.71%
Net Income Growth Q	27.24%
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Net Income Growth3 Y	-23.74%
Net Income Growth5 Y	-6.68%
Pretax Margin	5.75%
Profit Margin	3.31%
Profit Per Employee	NZD 3,072
Profitable Years	17
ROA	6.1
Roa5y	5.9
ROCE	12.67
ROE	12.46
Roe5y	12.87
ROIC	9.38
Roic5y	10.29

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	0.41%
Cagr15y	14.71%
Cagr1y	118.13%
Cagr3y	10.28%
Cagr5y	18.09%
Div CAGR10	-12.56%
Div CAGR3	-6.34%
Div CAGR5	-3.86%
EPS Growth	48.37
EPS Growth Q	26.97
EPS Growth Quarters	3
EPS Growth Years	1
EPS Growth3 Y	-23.79
EPS Growth5 Y	-6.72
FCF Growth	-7.45%
FCF Growth Q	-32.27%
FCF Growth3 Y	10.08%
FCF Growth5 Y	-10.05%
OCF Growth	-0.95%
OCF Growth Q	-14.58%
OCF Growth10 Y	-0%
OCF Growth3 Y	11.44%
OCF Growth5 Y	-7.27%
Revenue Growth	3.84x
Revenue Growth Q	1.75x
Revenue Growth Quarters	4x
Revenue Growth Years	2x
Revenue Growth3 Y	2.14x
Revenue Growth5 Y	3.39x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	NZD 1.35
Assets	NZD 392.9M
Cash	NZD 23.7M
Current Assets	NZD 85.6M
Current Liabilities	NZD 90.3M
Debt	NZD 136.5M
Debt EBITDA	NZD 2.35
Debt Equity	NZD 0.76
Debt FCF	NZD 3.47
Equity	NZD 180M
Interest Coverage	3.73
Liabilities	NZD 213M
Long Term Assets	NZD 307.4M
Long Term Liabilities	NZD 122.6M
Net Cash	NZD -112.9M
Net Cash By Market Cap	NZD -53.79
Net Debt EBITDA	NZD 2.6
Net Debt Equity	NZD 0.63
Net Debt FCF	NZD 2.87
Tangible Book Value	NZD 1.1M
Tangible Book Value Per Share	NZD 0.01
WACC	5.46

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.95
Inventory Turnover	13.92
Net Working Capital	NZD -14.6M
Quick ratio	0.57
Working Capital	NZD -4.8M
Working Capital Turnover	NZD -116

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.22%
Dividend Growth	27.79%
Dividend Growth Years	1%
Dividend per share	NZD 0.06
Dividend Years	5
Dividend Yield	4.11%
Ex Div Date	2025-12-04
Last Dividend	NZD 0.04
Payout Frequency	Semi-Annual
Payout Ratio	43.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	4.14%
1Y total return	118.02%
200-day SMA	1.08
3Y total return	34.14%
50-day SMA	1.29
50-day SMA vs 200-day SMA	50over200
5Y total return	129.6%
All Time High	2.95
All Time High Change	-50.51%
All Time High Date	2016-05-24
All Time Low	0.08
All Time Low Change	1,669.7%
All Time Low Date	2010-02-10
ATR	0.04
Beta	0.23
Beta1y	0.28
Beta2y	0.5
Ch YTD	39.05
High	1.48
High52	1.54
High52 Date	2026-02-12
High52ch	-5.19%
Low	1.46
Low52	0.71
Low52 Date	2025-05-09
Low52ch	105.63%
Ma50ch	13.09%
Price vs 200-day SMA	35.81%
RSI	61.21
RSI Monthly	67.76
RSI Weekly	68.13
Sharpe ratio	1.9x
Sortino ratio	3.58
Total Return	3.89%
Tr YTD	39.05
Tr15y	683.14%
Tr1m	17.74%
Tr1w	-0.68%
Tr3m	5.42%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	NZD 38.4M
Operating Income Growth	3.26
Operating Income Growth Q	7.91
Operating Income Growth3 Y	8.43
Operating Income Growth5 Y	-3.68
Operating margin	7.26

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	44,639,431%
Net Borrowing	-21,906,000
Shares Insiders	36.11%
Shares Institutions	8.9%
Shares Out	143,716,692
Shares Qo Q	-0.07%
Shares Yo Y	0.22%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	NZD 39.4M
Average Volume	24,147.9x
Bv Per Share	1.16
CAPEX	NZD -9.6M
Ch10y	-48.59
Ch15y	180.8
Ch1m	17.74
Ch1w	-0.68
Ch1y	102.8
Ch3m	5.42
Ch3y	11.45
Ch5y	39.05
Ch6m	55.32
Change	-1.35%
Change From Open	-1.35
Close	1.48
Days Gap	0
Depreciation Amortization	4,975,000
Dollar Volume	2,444
Earnings Date	2026-05-27
EBIT	NZD 38.4M
EBITDA	NZD 43.3M
EPS	NZD 0.12
F Score	5
FCF	NZD 39.4M
FCF EV Yield	11.74x
FCF Per Share	NZD 0.27
Financing CF	-43,144,000
Fiscal Year End	March
Founded	1,999
Graham Number	1.78449
Graham Upside	22.23
Income Tax	NZD 8.6M
Investing CF	-11,012,000
Is Primary Listing	1
Last Earnings Date	2026-02-26
Last Report Date	2025-09-30
Lynch Fair Value	NZD 0.61
Lynch Upside	-58.37
Ma150	1.15
Ma150ch	26.96%
Ma20	1.41
Ma20ch	3.62%
Net CF	-5,199,000
Next Earnings Date	2026-05-27
Open	1.48
P FCF Ratio	5.33
P OCF Ratio	4.29
Payment Date	2025-12-18
Position In Range	0
Ppne	117,857,000
Price Date	2026-05-08
Price EBITDA	NZD 4.84
Ptbv Ratio	190.2
Relative Volume	0.07x
Revenue	528,316,000x
Tax By Revenue	1.63x
Tax Rate	28.35%
Tr6m	60.24%
Volume	1,674
Z Score	2.25

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NZE/GXH dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+4.1%

$0.06 annual per share

Payout ratio

+43.2%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

-3.9%

1 consecutive years of growth

Total shareholder yield

+3.9%

Next ex-dividend date: 2025-12-04

Performance

NZE/GXH stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NZE/GXH?

Insider, institutional, and short-interest positioning.

Institutional ownership

+8.9%

Share of float held by funds and institutions

Insider ownership

+36.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.2%

Negative means the company is buying back shares.

Technical

NZE/GXH momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

61.2

Neutral momentum band

Price vs 200-day MA

+35.8%

50/200-day relationship not available

Beta (5Y)

0.23

Less volatile than the market

Sharpe ratio

1.90

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NZE/GXH

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nze/GXH stock rating?

nze/GXH is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nze/GXH analysis?

The full report lives at /stocks/nze/GXH/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nze/GXH?

The latest report frames nze/GXH around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nze/GXH page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.